Breaking News
Tucker Exposes Trump Would-Be Assassin Thomas Crooks' Social Media History, The FBI Coverup...
This Was A Major Red Flag In 2008, And Now It Is Happening Again!
A WORLD OF DEBT
Trump orders DOJ probe into Epstein's alleged ties with JPMorgan, Clinton and other Democrats
Top Tech News
Blue Origin New Glenn 2 Next Launch and How Many Launches in 2026 and 2027
China's thorium reactor aims to fuse power and parity
Ancient way to create penicillin, a medicine from ancient era
Unbanked In A Connected World
Goodbye, Cavities? Scientists Just Found a Way to Regrow Tooth Enamel
Scientists Say They've Figured Out How to Transcribe Your Thoughts From an MRI Scan
SanDisk stuffed 1 TB of storage into the smallest Type-C thumb drive ever
Calling Dr. Grok. Can AI Do Better than Your Primary Physician?
HUGE 32kWh LiFePO4 DIY Battery w/ 628Ah Cells! 90 Minute Build
What Has Bitcoin Become 17 Years After Satoshi Nakamoto Published The Whitepaper?
Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.